

Efavirenz/lamivudine/tenofovir disoproxil fumarate  
600 mg/300 mg/300 mg tablets  
(Cipla Ltd), HA593

WHOPAR part 8

March 2023

**Steps taken following Prequalification of [HA593 trade name]\*:**

<b>Changes</b>	<b>WHOPAR parts affected</b>	<b>Accepted on</b>
Addition of FPP manufacturing and batch control testing site	3	17 January 2017
Addition of FPP manufacturing and batch control testing site	3	24 January 2017
General update of the WHOPAR to reflect the current WHOPAR structure, product specifics, WHO guidelines and state of scientific knowledge	2, 3, 4	March 2023

---

\*Trade names are not prequalified by WHO. This is the national medicines regulatory authority's (NMRA) responsibility. Throughout this WHOPAR the proprietary name is given as an example only.